Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MacroGenics Inc.

www.macrogenics.com

Latest From MacroGenics Inc.

SOPHIA Positions MacroGenics' Margetuximab For Role In HER2-Positive Breast Cancer

MacroGenics' BLA for full approval in the US is under way and the company already has established a manufacturing facility in preparation for a launch.

Clinical Trials Research and Development Strategies

Start-Up Quarterly Statistics: A Record-Breaking Q2 As Financings Surge

Biopharma start-ups had a record-breading quarter in terms of fundraising. A review of biopharma start-up deal-making and financing activity from April through June 2018, based on data from Strategic Transactions.

Financing StartUps and SMEs

IPO Update: Returns Rebound As June Sees Its First New Biopharma Offering

MeiraGTx was the first to go public in the US in June after six drug developer IPOs launched in May. With returns for this year's first-time biopharma offerings more than doubling from 9% at the end of April to 23.6% as of June 8, four new companies have filed and six have set terms for future IPOs.

Financing Business Strategies

Denali Buyout Validates F-star’s Asset-Centric Model

Denali Therapeutics will pay around $470m in upfront and milestone payments to acquire its CNS bispecific antibody development partner F-star Gamma, lending credence to F-star’s business model of individual, asset-specific spin offs.    

M & A Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • MacroGenics Inc.
  • Senior Management
  • Scott Koenig, MD, PhD, Pres. & CEO
    James Karrels, SVP, CFO
    Ezio Bonvini, MD, SVP, Research & CSO
    Eric Risser, VP, Bus. Dev. & Portfolio Mgmt. & CBO
    Jon Wigginton, MD, SVP, Clin. Dev. & CMO
  • Contact Info
  • MacroGenics Inc.
    Phone: (301) 251-5172
    9704 Medical Center Dr.
    Rockville, MD 20850
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register